Clinical trials: Artery Occlusion
Femoral Artery Stenosis, Femoral Artery Occlusion
A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries
To assess the safety and efficacy of the BARD LTX DCB for treatment of stenosis or occlusion of the superficial femoral and popliteal arteries.
- Conditions
- Femoral Artery Stenosis, Femoral Artery Occlusion, Stenosis of Popliteal Arteries, Occlusion of Popliteal Arteries
- Trial name
- NCT02720003
- Testing
- LTX DCB
- Where
- 14 sites in China
- Volunteers
- 148 people
- Sponsor
- C. R. Bard
Peripheral Arterial Disease, Critical Limb Ischemia
ACPs in Severe PAD/CLI by Direct Intramuscular Injection
Study title: A Study of Blood-Borne Autologous Angiogenic Cell Precursors Therapy in Patients with Critical Limb Ischemia ( ACPs-CLI ) Principle Investigator: Assoc.Prof. Pramook Mutirangura,M.D.
- Trial name
- NCT00523731
- Testing
- Angiogenic Cell Precursors (ACPs) or Vescell TM
- Where
- Israel
- Volunteers
- 6 people
- Sponsor
- TheraVitae Ltd.
Atherosclerosis
Pharmacokinetics & Safety Study of Clopidogrel 75mg and Aspirin 100mg Coadministration
The purpose of this study is to compare characteristics and safety after oral administration of G0041(75/100mg) 2 tablets with those of Clopidogrel 75mg 2 tablets \& Aspirin 100mg 2 capsules coadministration in healthy male…
- Trial name
- NCT01526122
- Testing
- G0041(75/100mg), Clopidogrel & Aspirin
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Dong-A ST Co., Ltd.
Coronary Artery Disease (Left Main)
Clinical Study to Evaluate the STENTYS Xposition S for Treatment of Unprotected Left Main Coronary Artery Disease
Prospective, non-randomized, multi-center study assessing the long term safety and efficacy of the self expandable sirolimus eluting Xposition S stent in the treatment of unprotected left main coronary artery disease.
- Trial name
- TRUNC (NCT02800837)
- Where
- 4 sites in Italy, Switzerland and 1 more
- Volunteers
- 200 people
- Sponsor
- Stentys
Peripheral Arterial Disease
Short-term Perfusion Angiography Pilot Study (SPA)
The Short term Perfusion Angiography (SPA) study is designed to collect 2D Perfusion data from Critical Limb Ischemia (CLI) endovascular (interventional) procedures for information on device performance in a real-world setting.
- Trial name
- SPA (NCT03054636)
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Volcano Corporation
Heterozygous Familial Hypercholesterolaemia
Efficacy and Safety Study of Eprotirome in HeFH Patients Who Are on Optimal Standard of Care
Eprotirome is a liver selective thyroid hormone that can reduce several independent risk factors for cardiovascular disease, while an euthyroid state is preserved in the extrahepatic tissue.
- Trial name
- AKKA (NCT01410383)
- Testing
- Eprotirome
- Volunteers
- 236 people
- Sponsor
- Karo Bio AB
Coronary Artery Disease
The ENDEAVOR Pharmacokinetic (PK) Registry: The Medtronic Endeavor Drug Eluting Coronary Stent System
The purpose of this study is to evaluate the pharmacokinetics (PK) and safety associated with ABT-578 administered using the Medtronic Endeavor Drug Eluting Coronary Stent system in the treatment of single de novo lesions in…
- Trial name
- ENDEAVOR PK (NCT00314275)
- Testing
- Coronary Artery Stenting, Endeavor
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Medtronic Vascular
Intermittent Claudication
Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication
The purpose of this study is to evaluate the safety and pharmacokinetics of multiple, once-daily, intravenous doses of trans sodium crocetinate (TSC).
- Trial name
- NCT00725881
- Testing
- Trans sodium crocetinate (TSC), 0.9% normal saline
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Diffusion Pharmaceuticals Inc
Coronary Artery Disease, Congestive Heart Failure
Prognostic Indicators as Provided by the EPIC ClearView
The objective of this study is to determine whether the finger tip images captured by the EPIC ClearView device, when analyzed via the ClearView software, produce a Response Scale that characterizes trends consistent with known…
- Conditions
- Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation
- Trial name
- GBMC (NCT01476995)
- Where
- United States
- Volunteers
- 353 people, healthy volunteers welcome
- Sponsor
- Epic Research & Diagnostics, Inc.
Coronary Artery Disease, Coronary Artery Chronic Total Occlusion
CrossBoss and Stingray Catheter and Entera Guidewire Chronic Total Occlusion (CTO) Study
This study is to determine if the BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire) can facilitate safe and effective placement of a guidewire in the true lumen of coronary vessels distal to a…
- Trial name
- NCT00801710
- Testing
- BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)
- Where
- 4 sites in Germany
- Volunteers
- 42 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease, Cardiac Death
BioFreedom QCA Study in CAD Patients
This study aims to demonstrate that the BioFreedom™ Cobalt Chromium Drug Coated Stent is non-inferior to the market authorized BioFreedom™ Stainless Steel Stent with respective to efficacy and shows a similar safety profile.
- Conditions
- Coronary Artery Disease, Cardiac Death, Myocardial Infarction
- Trial name
- BioFreedomQCA (NCT03307213)
- Testing
- BioFreedom™ CoCr Biolimus A9™ stent, BioFreedom™ SS Biolimus A9™ stent
- Where
- 2 sites in Denmark, Spain
- Volunteers
- 200 people
- Sponsor
- Biosensors Europe SA
Peripheral Arterial Occlusive Disease
Clinical Post Market Clinical Follow-up (PMCF) on Peripheral Arteries Treated With SeQuent® Please Over The Wire (OTW)
The aim of the study is to assess the safety and efficacy of the paclitaxel-releasing balloon catheter SeQuent® Please OTW to treat de novo and restenotic lesions in peripheral arteries.
- Trial name
- CONSEQUENT (NCT02460042)
- Testing
- drug coated balloon angioplasty, SeQuent® Please OTW Paclitaxel Coated Balloon Catheter
- Where
- Germany
- Volunteers
- 960 people
- Sponsor
- B. Braun Melsungen AG
Atherosclerosis
An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism
The purpose of this study is to validate novel assays for serum biomarkers of lipid metabolism (PCSK9 and LDL receptor) and to obtain information about how these biomarkers differ in subjects with normal or high cholesterol levels
- Trial name
- NCT00847782
- Testing
- Blood draw
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Coronary Artery Disease
Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography
The purpose of this study is to demonstrate the (statistical) non-inferiority of iobitridol (Xenetix® 350) when compared to contrast agents with higher iodine concentrations, iopromide (Ultravist® 370) and iomeprol (Iomeron® 400)…
- Trial name
- X-ACT (NCT01255722)
- Testing
- iobitridol, iopromide, iomeprol
- Where
- 23 sites in France, Germany and 3 more
- Volunteers
- 468 people
- Sponsor
- Guerbet
Dementia, Alzheimer Disease
Feasibility of Passive Data Collection in Dementia Subjects With Agitation
This is a multi-center, observational, feasibility study, to evaluate long term passive data collection, data quality, and user experience of HealthMode Agitation (Apps) to collect motion, location, physiological, and audio data…
- Conditions
- Dementia, Alzheimer Disease, Vascular Dementia, Frontotemporal Dementia
- Trial name
- NCT04413851
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- HealthMode Inc.
Peripheral Arterial Disease
Study of NMB Drug Ejecting Balloon for Peripheral Arteries
The purpose of this study is to demonstrate the Safety and effectiveness of the use of NMB's drug ejecting balloon for the treatment of de novo and restenotic lesions in peripheral arterial disease.
- Trial name
- NCT01646801
- Testing
- NMB Balloon Catheter
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- N.M.B. Medical Applications Ltd
Coronary Disease, Coronary Artery Disease
XIENCE V® Everolimus Eluting Coronary Stent System India Post-marketing Single-arm Study
XIENCE V® India is a prospective, open-label, multi-center, observational, single-arm study to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- XIENCE V India (NCT00631228)
- Testing
- XIENCE V® Everolimus Eluting Coronary Stent
- Where
- 18 sites in India
- Volunteers
- 1,000 people
- Sponsor
- Abbott Medical Devices
Dementia, Alzheimer Disease
Efficacy Study of Kinto Care Coaching for Dementia Family Caregivers
The goal of this clinical trial is to evaluate Kinto's Care Coaching intervention for dementia caregivers. The main questions it aims to answer are: Does the intervention help caregivers to address their general caregiving goals…
- Conditions
- Dementia, Alzheimer Disease, Lewy Body Disease, Vascular Dementia
- Trial name
- NCT05916664
- Testing
- Kinto Care Coaching
- Where
- United States
- Volunteers
- 495 people, healthy volunteers welcome
- Sponsor
- Kinto
Peripheral Artery Disease, Access Site Complication
BIOTRONIK 4French for AMBulatory Peripheral Intervention
BIOTRONIK 4French for AMBulatory peripheral intervention. A multicenter, controlled trial comparing 4French versus 6French femoral access for endovascular treatment of lower-extremity peripheral artery disease in an ambulatory…
- Conditions
- Peripheral Artery Disease, Access Site Complication, Outpatient Treatment
- Trial name
- BIO4AMB (NCT03044002)
- Testing
- Biotronik 4 French Portfolio, 6 French Portfolio
- Where
- 5 sites in Austria, Belgium and 2 more
- Volunteers
- 821 people
- Sponsor
- Biotronik AG
Coronary Arteriosclerosis, Hypercholesterolemia
Comparative Atorvastatin Pleiotropic Effects
The primary objective of the study is to evaluate the efficacy of atorvastatin 80 mg daily as compared to atorvastatin 10 mg daily in reducing C-reactive protein levels over a 26-week treatment period in subjects with documented…
- Trial name
- CAP (NCT00163202)
- Testing
- Blood samples, Atorvastatin
- Where
- 74 sites in Canada, Czechia and 5 more
- Volunteers
- 330 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.